ImageneBio, Inc. (IMA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at ImageneBio, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 5.50 $ — 7% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralImageneBio ist trotz des KI-anmutenden Namens (eine Eindeutschung von »Inmagene«, dem fusionierten Biopharma-Unternehmen) eine klinische Ein-Produkt-Biotech: Leit- und einziger Wirkstoff ist der nicht-depletierende Anti-OX40-Antikörper IMG-007 gegen Neurodermitis. Kein KI-Produkt, kein KI-Umsatz (die Firma erzielt überhaupt keinen Produktumsatz), also kein »verkauft«. Kein »bedroht«: In den Risk Factors taucht »artificial intelligence« nur als generische Bedrohungs-/Regulierungs-Floskel auf (KI-gestützte Cyberangriffe, Deep Fakes, KI-Sektor-Regulierung nach OISP) ohne konkreten Bezug zum eigenen Geschäftsmodell. Auch kein »nutzt«: Der einzige Hinweis auf tatsächlichen KI-Einsatz ist ein beiläufiger Satz innerhalb eines Datenschutz-Risikofaktors, wonach Mitarbeiter generative KI-Werkzeuge bei ihrer Arbeit nutzen — kein dokumentiertes, wertschöpfendes KI-Programm (Effizienz/interne Produkte). Nach dem Kriterienkatalog verbleibt damit »Neutral« mit dokumentiertem Negativ-Befund; alle sechs ausgewerteten Filings sind gelistet.
View the full file — quotes, sources, reviewed filings
„As a result of the Non-OX40 Divestiture, IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of AD and other potential indications, became the only product candidate we have in clinical development."
Infolge der Non-OX40-Abspaltung wurde IMG-007, ein nicht-depletierender monoklonaler Anti-OX40-Antikörper zur Behandlung von Neurodermitis und weiteren möglichen Indikationen, zum einzigen Produktkandidaten, den wir in klinischer Entwicklung haben.
„Our personnel use generative artificial intelligence (“AI”) technologies to perform their work, and the disclosure and use of personal data in AI technologies is subject to various privacy laws and other privacy obligations."
Unsere Mitarbeiter nutzen generative Technologien der Künstlichen Intelligenz („KI“) bei ihrer Arbeit, und die Offenlegung und Nutzung personenbezogener Daten in KI-Technologien unterliegt verschiedenen Datenschutzgesetzen und weiteren Datenschutzpflichten.
Filings Reviewed: 10-Q 2026-05-07 · 10-Q 2025-11-12 · 10-Q 2025-07-24 · 10-Q 2025-05-08 · 10-K 2026-03-10 · 10-K 2025-03-06
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 336.4% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.90 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.81 | – | 0 | -100.00 | – | -6 | -6 |
| 2025: Q1 | -0.76 | – | 1 | – | -1,077.40 | -11 | -11 |
| 2025: Q2 | -0.25 | – | – | – | – | -3 | -3 |
| 2025: Q3 | -2.20 | – | 0 | -100.00 | – | -27 | -27 |
| 2025: Q4 | -0.61 | – | 0 | – | – | -7 | -7 |
| 2026: Q1 | -0.94 | – | 0 | -100.00 | – | -15 | -15 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
ImageneBio, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt Therapeutika für Patienten mit immunologischen, autoimmunen und entzündlichen Erkrankungen.
| Employees | 17 |
|---|---|
| Headquarters | San Diego, CA |
| Website | inmagenebio.com |
| IPO Date | 26. Mar 2021 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Kristin Yarema Ph.D. | CEO, Director & Interim Principal Financial Officer | 1971 |
| Bob Lally | Senior VP of Finance & Operations and Principal Accounting Officer | 1963 |
| Kurinji Pandiyan Ph.D. | Chief Strategy & Operations Officer | – |
| Renuka Sivendran Ph.D. | Chief Technical Officer | – |
| Benjamin Porter-Brown M.D. | Chief Medical Officer | 1973 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 25. Jul 2026 | Yarema Kristin | Chief Executive Officer | Other | 115,129 | 0.00 | – |
| 25. Jul 2026 | Yarema Kristin | Chief Executive Officer | Other | 38,376 | 0.00 | – |
| 17. Jul 2026 | Lally Robert B | Principal Accounting Officer | Sell | 1,525 | 5.34 | 8,144 |
| 16. Jul 2026 | Lally Robert B | Principal Accounting Officer | Sell | 1,671 | 5.50 | 9,191 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.